Help revolutionize the way Parkinson's disease is studied. Take an active role in groundbreaking research by mailing in your DNA sample and answering surveys online. Over 10,000 people with Parkinson's have come together to form what is now the largest Parkinson's community for genetic research in the world. This group is already powering research breakthroughs - we've found two new genes associated with Parkinson's.
With over 10,000 participants, we can make a bigger impact on Parkinson's research. Join today.
Muhammad Ali, the world's "Greatest" champion, is fighting alongside thousands of others who are part of the 23andMe Parkinson's Research Community. The more people who enroll in this research, the more powerful it becomes, and the more likely it is that we can find a cure for Parkinson's. Encourage people you know with Parkinson's to enroll online. Spread the word!
Recently our scientists found a genetic variant that appears to be protective against Parkinson's. This major breakthrough was possible only because of participation from people who don't have the disease. Breakthroughs can lead to cures or preventions so people don't get sick in the first place. By joining 23andMe and simply choosing to take part in research by answering questions, you can contribute to scientific discoveries - not only related to Parkinson's, but related to hundreds of other conditions. Plus, you can learn about your ancestry and access your raw genetic data through the 23andMe Personal Genome Service®.
You don't have to join 23andMe to give a hand to someone with Parkinson's. It doesn't take heroic gestures to support those with the disease. A first step is simply learning more about Parkinson's. The Michael J. Fox Foundation offers "Parkinson's 101" to help explain what it is and how it affects the brain. Sometimes just being there and listening is all that matters. Their "Guide for Caregivers" offers more suggestions and tips.
J. William Langston, M.D. is Chief Scientific Officer and Founder of the Parkinson's Institute in Sunnyvale, California. A graduate of the University of Missouri School of Medicine, he served as a faculty member at Stanford University Medical School and Chairman of Neurology at Santa Clara Valley Medical Center in San Jose, California before founding the Parkinson's Institute. He has authored or co-authored 360 publications in the field of neurology, most of which are on Parkinson's disease and related disorders. He is the founding member of the Scientific Advisory Board for the Michael J. Fox Foundation for Parkinson's Research, on which he continues to serve. Dr. Langston's current research interests include the study of mechanisms of neuronal degeneration, the etiology of Parkinson's disease, the development of new strategies to slow or halt disease progression, and ways to identify the disease in its earliest “pre-motor” stages.
Caroline M. Tanner, M.D., Ph.D. is the Director of Clinical Research at The Parkinson's Institute and Clinical Center. Dr. Tanner earned her medical degree at Loyola University (1976) and completed a residency in Neurology and a fellowship in Clinical Neuropharmacology and Movement Disorders at Rush-Presbyterian-St. Luke's Medical Center, where she was an Associate Professor of Neurological Sciences until joining the Parkinson's Institute in 1990. She was awarded a Ph.D. in Environmental Toxicology & Epidemiology from the University of California, Berkeley in 1998. During her 27-year long medical career, Dr. Tanner has published two textbooks and a videotext, and authored or co-authored over 150 articles and research papers on the topics of treatment, natural history, epidemiology, and etiology of various movement disorders.
Joseph Jankovic, M.D. is the Director of the Parkinson's Disease Center and Movement Disorders Clinic as well as a distinguished Professor of Neurology at the Baylor College of Medicine. After completing his chief residency in Neurology at the Neurological Institute of Columbia University, Dr. Jankovic joined the faculty of Baylor College of Medicine in 1977 and founded the Parkinson's Disease Center and Movement Disorders Clinic. Dr. Jankovic has served as the principal investigator on dozens of clinical trials, has published over 800 original articles and book chapters, and has edited or co-edited 40 books. Dr. Jankovic is a member of the Executive Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Research and the Clinical and Scientific Advisory Board of the National Parkinson Foundation. He has served on editorial boards of Neurology, Movement Disorders, Journal of Neurology Neurosurgery and Psychiatry, Acta Neurologica Scandinavica, Journal of Neurological Sciences, Journal of Parkinson's Disease, Neurology Medlink, and other journals.
Philip LoGrasso, Ph.D. is a Professor in the Molecular Therapeutics Department and Senior Director of Drug Discovery in the Translational Research Institute within The Scripps Research Institute where he has been since 2005. Dr. LoGrasso received his B.A. in chemistry from New York University in 1985, his M.S. in biochemistry from Florida State University in 1988, and his Ph.D. in pharmacology from the University of Florida in 1992. This was followed by post- doctoral training at the Sandoz Research Institute (now Novartis). Prior to joining Scripps Florida, Dr. LoGrasso was a Program Officer at the NIH and had responsibility for funding a $50M research portfolio of grants in the areas of chemical biology, medicinal chemistry, pharmacology, and postdoctoral and graduate training fellowships. He currently serves on the scientific advisory board for Envoy Therapeutics and Arrien Pharmaceuticals. Both of these companies are focused on developing novel therapeutics for central nervous system disorders, especially Parkinson's disease.